Navigation Links
Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth
Date:10/15/2008

CLEVELAND, Ohio and TEL AVIV, Israel, October 15 /PRNewswire/ -- Simbionix USA Corporation is pleased to announce the completion of a Series C round of growth capital financing led by River Cities Capital Funds, along with incumbent investor Early Stage Partners and other existing shareholders, as well as Western Reserve Partners who served as the company's investment bankers. The investment will enable Simbionix to accelerate the already rapid growth of its medical simulation technology via the introduction of innovative new products and expanded distribution channels. "This significant funding will help us continue the company's momentum and support Simbionix's commitment to maintain its position as the global leader in medical simulation technology," stated Dr. Avshalom Horan, Chairman.

"We are excited about the market's validation of our technology as well as the strong financial support of River Cities and the continuing support of our existing investors," commented Gary Zamler Simbionix CEO. "This infusion of new growth capital will fuel further domestic and international growth of our existing products as well as our emerging products - that includes the recently launched PROcedure Rehearsal Studio, a truly revolutionary virtual reality endovascular simulator with unprecedented hands-on, "patient-specific training capabilities," he added. "Simbionix works closely with global leaders in healthcare, both on the medical device side and the provider side. They take comfort with Simbionix as a partner because of our size, profitability, and the resources to bring innovative products to market," Mr. Zamler concluded.

Ran Bronstein, Simbionix President and one of its founders commented "funding of this sort is an important achievement for the Simbionix team. It's an additional indication demonstrating the growth and the validity of the medical education and simulation market since River Cities has experience in both fields. We welcome River Citi
'/>"/>

SOURCE Simbionix Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. 2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators
2. Simbionix Takes Non-Invasive GYN Surgical Training to the Next Level
3. Simbionix Releases Powerful New Learning Management System With Enhanced True Assessment System(TM)
4. Simbionix Launches Innovative Patient-Specific Simulation
5. Pearl Therapeutics Raises $15.5 Million in Private Financing
6. Enobia Pharma Raises $40.1 Million Series B Financing
7. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
8. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
9. VisEn Medical Raises $7 Million in Series B Financing
10. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
11. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...hybrid . . . , Fuel economy ratings for the ne...e www.fueleconomy.gov web site, which Oak Ridge ...e U.S. Department of Energy and the U.S. Environme...s on the best fuel economy list are hybrid electri...ay). "This list proves that hybrids have gone main...
(Date:11/5/2009)... 5 DSM Pharmaceutical Products tod...ance with Galenix, Saint Jean D,Illac, France, whe...facturing partner for Galenix commercial products ...aborate on business development opportunities co-m... on the strength of Galenix in drug product develo...
(Date:11/5/2009)...rsday, November 5, 2009 at 4:30 p.m. Eastern Time ...e-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("O... reported unaudited financial results for the thir... and reviewed the Company,s highlights for the thi...ed results reflect the operations of OncoGenex Tec...
(Date:11/5/2009).... 5 Cepheid (Nasdaq: CP...peaking at the following investor conferences, and... Credit Suisse Healthcare Conferen...mber, 2009 at 10 a.m. Mountain Time, ...and, Tuesday, 1 December, 2009 at ...
Breaking Biology Technology:November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2
...o and TEL AVIV, Israel, October 15 ,Simbionix USA ...of a Series,C round of growth capital financing le...nt investor Early Stage Partners and other existin...s who served as the,company,s investment bankers. ... the already rapid growth of its medical simulatio...
... Medical Education Agency Expanding Industry Conne...re,Communications LLC, an independent, full-servic...ring of Todd Weinstein as Vice President, Business...ence in medical education and,publishing as the he...he,served as Manager of Publication Sales at McMah...
..., Oct. 15 The increased emphasis on,safety by reg...medical,product development programs and requires ...ns by Sponsors to respond appropriately. Expertise...sulting organizations. GZP,has already emplaced sy...s,that can lead to adverse regulatory action by th...
Other Biology Technology:Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 2Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 3L&M Healthcare Communications LLC Expands Client Services With Executive Team Expansion 2Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 2Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 3
(Date:11/6/2009)... Center and the Chinese Academy of Sciences (CAS) ...on Taste and Smell Research. Organized by Monell i...the first international meeting on taste and smell...utive Officer, American Association for the Advanc...e magazine, will open the meeting with a plenary a...
(Date:11/4/2009)...ant to officially endorse green tea as a cancer pr...its protective effects, including results of a new...a journal of the American Association for Cancer R...cer. , Vassiliki Papadimitrakopoulo, M.D., prof...ad and Neck Medical Oncology at the University of ...
(Date:11/4/2009)..., hold the power to help militaries and munitions ...ic waste on test sites. , Compounds known as nit...orld War II and have been used in military munitio...ften used to propel tank shells and act like a mor...d knowledge of their environmentally harmful effec...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2Genomic research will enable greener cleanup of military explosive test sites 2IMRIS receives FDA clearance for IMRISNV and IMRIScardio 56403 1IMRIS receives FDA clearance for IMRISNV and IMRIScardio 56403 2Cochlear Americas Announces FDA Approval of the Nucleus 28R 29 5 System the Newest and Most Advanced Cochlear Implant System 56401 1Cochlear Americas Announces FDA Approval of the Nucleus 28R 29 5 System the Newest and Most Advanced Cochlear Implant System 56401 2Cochlear Americas Announces FDA Approval of the Nucleus 28R 29 5 System the Newest and Most Advanced Cochlear Implant System 56401 3Cochlear Americas Announces FDA Approval of the Nucleus 28R 29 5 System the Newest and Most Advanced Cochlear Implant System 56401 4New York Giants to Host American Red Cross Blood Drive 56398 1New York Giants to Host American Red Cross Blood Drive 56398 2
...ee of large-scale catastrophes to pursue their dre...epartment of Homeland Security (DHS) is the federa...errorist attacks and making it a more secure place...ough its Science & Technology (S&T) Directorate, w... leads to products, systems and services that help...
...etable oil and other renewable sources are increas...s as a way to reduce fossil fuel dependence and li... led by a biologist at the University of Washingto...rrent biofuel stocks might have exactly the opposi...ublished in the June issue of the journal Conserva...
...t a fundamental building block in the cells of flo...entically, on a separate branch of the evolutionar...s that originated at least 420 million years ago. ...ved from gymnosperms, the group that includes coni... from lycophytes hundreds of millions of years bef...
Other Biology News:DHS, business leaders discuss technology to protect US at Homeland Security conference 2DHS, business leaders discuss technology to protect US at Homeland Security conference 3Some biofuels might do more harm than good to the environment, study finds 2Some biofuels might do more harm than good to the environment, study finds 3When plants 'think' alike 2
Mouse Anti-Human HLA Class II DQ1 7 Monoclonal Antibody, Unconjugated, Clone 4i144 from Abcam
Anti-ASCIZ Antibody, Unconjugated from CHEMICON
Goat Anti-CHMP5 Polyclonal Antibody, Unconjugated from Abcam
Custom Oligo Assay Single Locus 1920 samples from Illumina
Biology Products: